Journal
EPILEPSIA
Volume 54, Issue -, Pages 24-34Publisher
WILEY
DOI: 10.1111/epi.12296
Keywords
Antiseizure drug; Pharmacoresistant epilepsy; Animal models of epilepsy
Categories
Funding
- NIH (NINDS) [271201100029C]
- Desitin
- Eisai Ltd
- GlaxoSmithKline
- UCB Pharma
- Biotechnology and Biological Sciences Research Council
- Epilepsy Research UK
- European Commission
- National Institute of Health Research
- Wellcome Trust
- UCB
- Bial
- Eisai Inc.
- V(sic)astraG(sic)otaland Region
- NIH [NICHD F32HD070836-01, NINDS NS-20253, NS-43209, NS-45911, NS-78333]
- Department of Defense
- CURE
- Heffer Family Medical Foundation
- Segal Family Foundation
- FDA
- American Epilepsy Society
- Epilepsy Foundation
- Neuren Pharmaceuticals
- Eisai
- NINDS [NS072094, NS079202, NS077582]
- Epilepsy Therapy Project
- Gilead Sciences
Ask authors/readers for more resources
This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). Wereview here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. Wealso briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available